Early-onset cancer fuels calls for wider screening — but at what cost?
(feeds.nature.com)
1.
2.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
(feeds.content.dowjones.io)
3.
Engaging the head and the heart: why scientists turn to poetry
(feeds.nature.com)
4.
AstraZeneca’s Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer
(feeds.content.dowjones.io)
Today's top topics:
openai
chatgpt
android authority
claude
bike fitting
cycling
show hn
google
nasa